- Home
- ORMP vs NYXH Comparison
ORMP vs NYXH Comparison
Compare ORMP & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORMP | NYXH |
|---|---|---|
| Founded | 2002 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.3M | 161.9M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ORMP | NYXH |
|---|---|---|
| Price | $4.07 | $1.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | ★ 506.9K | 308.3K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | ★ 412.50 | N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $2,000,000.00 | N/A |
| Revenue This Year | N/A | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | $4.59 | ★ N/A |
| Revenue Growth | ★ 49.25 | N/A |
| 52 Week Low | $1.98 | $1.26 |
| 52 Week High | $5.19 | $8.59 |
Technical Indicators
Market Signals| Indicator | ORMP | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 40.87 |
| Support Level | $3.29 | $1.26 |
| Resistance Level | $4.22 | $3.36 |
| Average True Range (ATR) | 0.35 | 0.11 |
| MACD | -0.04 | 0.06 |
| Stochastic Oscillator | 17.65 | 57.14 |
Price Performance
Historical ComparisonAbout ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.